JW Creagene finishes patent registration for manufacturing dendritic cell therapies in Europe
JW Creagene finishes patent registration for manufacturing dendritic cell therapies in Europe
  • Lee Jun-sung
  • 승인 2020.03.05 12:56
  • 댓글 0
이 기사를 공유합니다

Image source = JW creagene

JW Creagene has proven its new technology for manufacturing dendritic cell therapies in Europe and Japan.

JW Creagene, a subsidiary of JW Shinyak, said on March 4 that it has completed patent registration for new biomanufacturing technology using dendritic cells (DC) to European and Japanese patent offices.

The patent is a technology independently developed by JW Creagene on "how to manufacture dendritic cells, and their uses." In Europe, the company plans to obtain individual patents within the first half of the year after entering major countries.

JW Creagene has a drug delivery technology (CTP, Cytoplasmic transduction peptide) and is developing an immune cell therapy called "CreaVax" that utilizes it.

The dendritic cells instruct T cells in charge of immunity in the body to attack certain cells, such as cancer cells, and can be developed as various treatments depending on antigen (a substance that induces immune reactions).

JW Creagene currently has new drug pipelines such as CREAVax-HCC, which is in clinical trial phase 3 and CreaVax-BC, which is in clinical trial phase 1/2.

"With the global patent strategy, we will be recognized for our unique technology and rights in the field of dendritic cells therapy," said CEO Lee Kyung-joon of JW Creagene. "We will secure our competitiveness in the rapidly growing next-generation anti-cancer drug market through successful commercialization and creation of value-added products such as technology transfer."


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.

  • #1206, 36-4 Yeouido-dong, Yeongdeungpo-gu, Seoul, Korea(Postal Code 07331)
  • 서울특별시 영등포구 여의도동 36-4 (국제금융로8길 34) / 오륜빌딩 1206호
  • URL: www.koreaittimes.com / m.koreaittimes.com. Editorial Div. 02-578-0434 / 010-2442-9446. Email: info@koreaittimes.com.
  • Publisher: Monica Younsoo Chung. CEO: Lee Kap-soo. Editor: Jung Yeon-jin. Juvenile Protection Manager: Yeon Choul-woong.
  • IT Times Canada: Willow St. Vancouver BC, Canada / 070-7008-0005.
  • Copyright(C) Korea IT Times, Allrights reserved.
ND소프트